Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Fig. 4

Mean (SE) HAQ-DI scores over time (observed). Baseline qualifying index study data were used for approximately 90% of patients. Italicized data not reported in figure due to low patient numbers. Data for 12-month intervals are reported in the table. Database lock: March 2, 2017. BID twice daily, BL baseline, HAQ-DI Health Assessment Questionnaire-Disability Index, SE standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us